Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
LENZ Stock Forecast 2026-2027
$10.18
Current Price
$319.19M
Market Cap
Buy 7
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to LENZ Price Targets
+489.4%
To High Target of $60.00
+283.1%
To Median Target of $39.00
+96.5%
To Low Target of $20.00
LENZ Price Momentum
+12.2%
1 Week Change
-11.4%
1 Month Change
-57.3%
1 Year Change
-36.4%
Year-to-Date Change
-79.8%
From 52W High of $50.40
+23.4%
From 52W Low of $8.25
📊 TOP ANALYST CALLS
Did LENZ Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if LENZ Therapeutics is one of their latest high-conviction picks.
Latest LENZ Stock Price Targets & Analyst Predictions
Based on our analysis of 8 Wall Street analysts, LENZ has a bullish consensus with a median price target of $39.00 (ranging from $20.00 to $60.00). The overall analyst rating is Strong Buy (9.7/10). Currently trading at $10.18, the median forecast implies a 283.1% upside. This outlook is supported by 7 Buy, 0 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
LENZ Analyst Ratings
7
Buy
0
Hold
0
Sell
LENZ Price Target Range
Low
$20.00
Average
$39.00
High
$60.00
Current: $10.18
Latest LENZ Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for LENZ.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 26, 2026 | Citigroup | Yigal Nochomovitz | Buy | Maintains | $26.00 |
| Mar 25, 2026 | B of A Securities | Jason Gerberry | Buy | Maintains | $29.00 |
| Oct 20, 2025 | Raymond James | Gary Nachman | Outperform | Reiterates | $50.00 |
| Oct 10, 2025 | Piper Sandler | Biren Amin | Overweight | Maintains | $67.00 |
| Aug 1, 2025 | Citigroup | Yigal Nochomovitz | Buy | Maintains | $52.00 |
| Aug 1, 2025 | HC Wainwright & Co. | Matthew Caufield | Buy | Maintains | $56.00 |
| Jul 31, 2025 | Citigroup | Yigal Nochomovitz | Buy | Maintains | $49.00 |
| Jul 31, 2025 | Raymond James | Gary Nachman | Outperform | Maintains | $40.00 |
| Jul 28, 2025 | HC Wainwright & Co. | Matthew Caufield | Buy | Maintains | $48.00 |
| May 8, 2025 | HC Wainwright & Co. | Matthew Caufield | Buy | Reiterates | $38.00 |
| Apr 16, 2025 | HC Wainwright & Co. | Matthew Caufield | Buy | Reiterates | $38.00 |
| Apr 14, 2025 | Piper Sandler | Biren Amin | Overweight | Maintains | $51.00 |
| Mar 20, 2025 | Citigroup | Yigal Nochomovitz | Buy | Maintains | $47.00 |
| Nov 7, 2024 | HC Wainwright & Co. | Matthew Caufield | Buy | Reiterates | $38.00 |
| Sep 27, 2024 | Raymond James | Gary Nachman | Outperform | Initiates | $37.00 |
| Aug 15, 2024 | Piper Sandler | Joseph Catanzaro | Overweight | Maintains | $36.00 |
| Aug 15, 2024 | HC Wainwright & Co. | Matthew Caufield | Buy | Reiterates | $38.00 |
| Aug 12, 2024 | HC Wainwright & Co. | Matthew Caufield | Buy | Initiates | $38.00 |
| Apr 15, 2024 | William Blair | Tim Lugo | Outperform | Initiates | $N/A |
| Apr 15, 2024 | Leerink Partners | Marc Goodman | Outperform | Initiates | $32.00 |
LENZ Therapeutics, Inc. (LENZ) Competitors
The following stocks are similar to LENZ Therapeutics based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
LENZ
LENZ Therapeutics
mkt cap
319.19M
LENZ Therapeutics, Inc. (LENZ) Financial Data
LENZ Therapeutics, Inc. has a market capitalization of $319.19M with a P/E ratio of 48.0x. The company generates $19.09M in trailing twelve-month revenue with a 97.8% profit margin.
Revenue growth is -87.3% quarter-over-quarter, while maintaining an operating margin of -2,422.1% and return on equity of -33.6%.
Valuation Metrics
Market Cap
$319.19M
Enterprise Value
$27.66M
P/E Ratio
48.0x
PEG Ratio
0.3x
Price/Sales
16.7x
Growth & Margins
Revenue Growth (YoY)
-87.3%
Gross Margin
N/A
Operating Margin
-2,422.1%
Net Margin
+97.8%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+91.6%
Current Ratio
14.2x
Debt/Equity
0.3x
ROE
-33.6%
ROA
-21.9%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
LENZ Therapeutics, Inc. (LENZ) Business Model
About LENZ Therapeutics, Inc.
What They Do
Pharmaceutical company specializing in eye drop solutions.
Business Model
The company generates revenue through the commercialization of its FDA-approved product, VIZZ™, an aceclidine ophthalmologic solution designed to treat presbyopia. LENZ Therapeutics markets VIZZ™ in the United States and seeks to expand its reach through international licensing partnerships, allowing for broader access to its innovative treatment.
Additional Information
LENZ Therapeutics is headquartered in Solana Beach, California, and is led by a team with extensive experience in biopharmaceutical development and commercialization. Their product aims to provide an alternative to reading glasses for adults over 45, catering to a significant market need for improved near vision.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
152
CEO
Mr. Evert B. Schimmelpennink
Country
United States
IPO Year
2024
Website
www.lenz-tx.comLENZ Therapeutics, Inc. (LENZ) Latest News & Analysis
Latest News
LENZ Therapeutics: Speculative But Strong Buy
18 days ago
Quick Summary
LENZ Therapeutics' Vizz eye drop for presbyopia presents a high-risk, high-reward opportunity. A conservative fair value estimate is $25/share, suggesting ~200% upside, pending refill rate disclosures.
Why It Matters
LENZ Therapeutics' Vizz eye drop offers significant upside potential, with a conservative valuation of $25/share. Market interest hinges on refill rates and management's upcoming disclosures, amid side effect concerns.
Source: Seeking Alpha
Market Sentiment:
Negative
Quick Summary
VIZZ, a newly commercialized treatment for blurry vision, has not yet made a significant impact in the market.
Why It Matters
VIZZ's lackluster market performance despite high expectations for its blurry vision treatment may signal potential volatility, impacting investor sentiment and stock valuation.
Source: The Motley Fool
Market Sentiment:
Neutral
Why Lenz Therapeutics Stock Crashed Today
26 days ago
Quick Summary
Lenz reported missed sales and Q4 earnings. The company aims for 45,000 prescriptions of its vision drug VIZZ by the end of Q1.
Why It Matters
Lenz's earnings and sales miss may signal operational challenges, impacting investor confidence. However, the prescription target for VIZZ could indicate potential for future revenue growth.
Source: The Motley Fool
Market Sentiment:
Negative
Quick Summary
LENZ Therapeutics, Inc. (LENZ) held its Q4 2025 earnings call, discussing financial performance and future outlook. Detailed results were shared in the transcript.
Why It Matters
LENZ's Q4 2025 earnings reveal financial performance and strategic direction, impacting stock valuation, investor confidence, and potential future growth opportunities.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
LENZ Therapeutics launched VIZZ® (aceclidine ophthalmic solution) for presbyopia in October 2025, generating $1.6 million in Q1 2026 with over 45,000 prescriptions filled.
Why It Matters
Strong early sales and broad prescriber adoption of VIZZ indicate significant market potential and revenue growth for LENZ Therapeutics, enhancing investor confidence in the company's future.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
LENZ Therapeutics reported a quarterly loss of $1.16 per share, exceeding the Zacks Consensus Estimate of a $0.91 loss, and worsening from a $0.46 loss per share a year prior.
Why It Matters
LENZ's larger-than-expected quarterly loss signals worsening financial health, potentially impacting stock value and investor sentiment negatively.
Source: Zacks Investment Research
Market Sentiment:
Negative
Frequently Asked Questions About LENZ Stock
What is LENZ Therapeutics, Inc.'s (LENZ) stock forecast for 2026?
Based on our analysis of 8 Wall Street analysts, LENZ Therapeutics, Inc. (LENZ) has a median price target of $39.00. The highest price target is $60.00 and the lowest is $20.00.
Is LENZ stock a good investment in 2026?
According to current analyst ratings, LENZ has 7 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $10.18. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for LENZ stock?
Wall Street analysts predict LENZ stock could reach $39.00 in the next 12 months. This represents a 283.1% increase from the current price of $10.18. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is LENZ Therapeutics, Inc.'s business model?
The company generates revenue through the commercialization of its FDA-approved product, VIZZ™, an aceclidine ophthalmologic solution designed to treat presbyopia. LENZ Therapeutics markets VIZZ™ in the United States and seeks to expand its reach through international licensing partnerships, allowing for broader access to its innovative treatment.
What is the highest forecasted price for LENZ LENZ Therapeutics, Inc.?
The highest price target for LENZ is $60.00 from at , which represents a 489.4% increase from the current price of $10.18.
What is the lowest forecasted price for LENZ LENZ Therapeutics, Inc.?
The lowest price target for LENZ is $20.00 from at , which represents a 96.5% increase from the current price of $10.18.
What is the overall LENZ consensus from analysts for LENZ Therapeutics, Inc.?
The overall analyst consensus for LENZ is bullish. Out of 8 Wall Street analysts, 7 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $39.00.
How accurate are LENZ stock price projections?
Stock price projections, including those for LENZ Therapeutics, Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: April 19, 2026 5:52 PM UTC